SubSynD: Subsyndromal Delirium in Intensive Care Unit

Sponsor
Centro Hospitalar Lisboa Ocidental (Other)
Overall Status
Completed
CT.gov ID
NCT03813459
Collaborator
Orion Corporation, Orion Pharma (Industry)
400
1
20
20

Study Details

Study Description

Brief Summary

Subsyndromal delirium (SSD) is a condition characterized by a less severe cognitive impairment in comparison to delirium. To date there is no published consensus on SSD definitions and has been commonly reported as an intermediate stage between delirium and normal mental states.

SSD encompasses some of the delirium symptoms, and has been diagnosed with Intensive Care Delirium Screening Checklist scale (ICDSC) and Confusion Assessment Method-ICU (CAM-ICU).

The objective of this study is to identify subsyndromal delirium prevalence, the association between SSD and clinical outcomes and understanding the relationship between SSD and conversion to delirium.

The relevance of this study is understanding of subsyndromal delirium in ICU, namely the importance of early presentations of acute brain dysfunction in the patients outcome.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    SubSynD is a prospective, observational, multicenter clinical study, involving 400 patients in Intensive Care Units, to assess subsyndromal delirium.

    A systematic screening for delirium and subsyndromal delirium (SSD) is done with Intensive Care Delirium Screening Checklist (ICDSC) and Confusion Assessment Method-ICU (CAM-ICU). Scales are applied once per day until ICU discharge or for up to 14 days of being in ICU.

    The investigators access three different groups of patients: non-delirium, delirium and subsyndromal delirium. It is intended that either ICDSC or CAM-ICU, paired with a Richmond Agitation and Sedation Scale (RASS) be administered once per day (i.e. with first assessment in the morning). All patients with abnormal CAM-ICU or ICDSC features, beside the underlying cause of delirium and SSD are included. In addition, data regarding baseline demographic and clinical characteristics will be collected as well as data regarding the procedure performed (see Case Report Form (CRF)).

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    400 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Subsyndromal Delirium in Intensive Care Unit, a Multicenter Study
    Actual Study Start Date :
    Aug 1, 2018
    Actual Primary Completion Date :
    Sep 1, 2019
    Actual Study Completion Date :
    Mar 31, 2020

    Arms and Interventions

    Arm Intervention/Treatment
    Subsyndromal delirium positive

    Presence of Subsyndromal delirium in Intensive Care patients

    Delirium positive

    Presence of Delirium in Intensive Care patients

    No delirium

    Non subsyndromal delirium or delirium in Intensive Care patients

    Outcome Measures

    Primary Outcome Measures

    1. Number of patients with conversion from subsyndromal delirium to delirium during the period of study [14 days]

      ICDSC performed 1 time per day and determine how subsyndromal delirium (ICDSC 1-3) can have conversion to delirium (ICDSC >/=4).

    2. Mortality [28 days]

      defined as number of days that patients survived in 28 days

    3. Ventilation free days [28 days]

      defined has the number of days from day 1 to day 28 on which a patient breathed without assistance

    Secondary Outcome Measures

    1. ICU length of stay [24 months]

      days until ICU discharge

    2. Hospital length of stay [24 months]

      days until ICU discharge

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 100 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Age ≥ 18 years;

    2. Admission in Intensive care Unit

    Exclusion Criteria:
    1. Primary neurological diagnosis, with Glasgow Coma Scale (GCS) <14 on ICU admission or in previous days;

    2. Blindness or deafness;

    3. Aphasia;

    4. Inability to communicate in the native language of the country where the study is enrolled;

    5. Death during the first 24 hours;

    6. Limitation of therapeutic efforts in the Intensive Care Unit admission;

    7. Refusal to participate;

    8. Previous diagnosis of dementia or psychiatric illness;

    9. Readmission in ICU;

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Maria Carolina Vieira Júlio Paulino Lisboa Portugal 1300-346

    Sponsors and Collaborators

    • Centro Hospitalar Lisboa Ocidental
    • Orion Corporation, Orion Pharma

    Investigators

    • Study Director: Maria C Paulino, MD, Centro Hospitalar de Lisboa Ocidental

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Maria Carolina Vieira Júlio Paulino, Principal Investigator, Centro Hospitalar Lisboa Ocidental
    ClinicalTrials.gov Identifier:
    NCT03813459
    Other Study ID Numbers:
    • UCIP1
    First Posted:
    Jan 23, 2019
    Last Update Posted:
    Dec 14, 2021
    Last Verified:
    Dec 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Maria Carolina Vieira Júlio Paulino, Principal Investigator, Centro Hospitalar Lisboa Ocidental
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 14, 2021